RNAC
Selecta Biosciences Inc

7,734
Mkt Cap
$192.95M
Volume
149,256.00
52W High
$20.00
52W Low
$5.98
PE Ratio
-0.14
RNAC Fundamentals
Price
$7.42
Prev Close
$7.36
Open
$7.53
50D MA
$7.38
Beta
1.75
Avg. Volume
255,984.36
EPS (Annual)
-$4.48
P/B
-5.38
Rev/Employee
$589,590.91
Loading...
Loading...
News
all
press releases
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm...
MarketBeat·1mo ago
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm...
MarketBeat·2mo ago
News Placeholder
What is HC Wainwright's Estimate for RNAC FY2025 Earnings?
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings per share estimates for Cartesian Therapeutics in a research note issued on...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price
HC Wainwright cut their price target on Cartesian Therapeutics from $40.00 to $30.00 and set a "buy" rating for the company in a report on Wednesday...
MarketBeat·2mo ago
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Given New $44.00 Price Target at BTIG Research
BTIG Research increased their price objective on Cartesian Therapeutics from $42.00 to $44.00 and gave the company a "buy" rating in a research note on Friday...
MarketBeat·2mo ago
News Placeholder
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.read more...
Benzinga·2mo ago
News Placeholder
Cantor Fitzgerald Issues Negative Estimate for RNAC Earnings
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Cartesian Therapeutics in a research report issued to...
MarketBeat·2mo ago
News Placeholder
Wedbush Has Negative Forecast for RNAC FY2025 Earnings
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at Wedbush cut their FY2025 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on...
MarketBeat·2mo ago
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results, Misses Estimates By $0.57 EPS
Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) announced its earnings results on Thursday. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·2mo ago
<
1
2
...
>

Latest RNAC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.